Skip to main content
SpringerLink
Log in

Radiomics in Hepatocellular Carcinoma

  • Review Article
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Background

Radiomics is an emerging field that extracts high-throughput imaging data from different types of images to build models and predict clinical outcomes ina non-invasive manner. This field currently is in the initial growth phase and lacks standardized evaluation criteria but remains a very promising tool for the future todevelop suitable biomarkers for diagnosis, prognosis, and treatment response assessments. The analysis of hepatocellular carcinoma by radiomics will contribute toearly diagnosis and treatment of tumors and improve survival and cure rates.

Aim

Herein, we aimed to provide an up-to-date overview of the principles of radiomics specifically regarding hepatocellular carcinoma (HCC) and discuss the current challenges and future advancements of radiomics for HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Data Availability

Not applicable.

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.

    PubMed  Google Scholar 

  2. Hiley C, de Bruin EC, McGranahan N, Swanton C. Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine. Genome Biol. 2014;15:453.

    Article  PubMed  Google Scholar 

  3. Hesketh RL, Zhu AX, Oklu R. Hepatocellular carcinoma: can circulating tumor cells and radiogenomics deliver personalized care? Am J Clin Oncol. 2015;38:431–6.

    Article  CAS  PubMed  Google Scholar 

  4. Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med. 2006;12:410–6.

    Article  CAS  PubMed  Google Scholar 

  5. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Cmargo A, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med. 2008;359:1995–2004.

    Article  CAS  PubMed  Google Scholar 

  6. Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B, Llovet JM. Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis. 2010;30:35–51.

    Article  CAS  PubMed  Google Scholar 

  7. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19(3):329–38.

    Article  CAS  PubMed  Google Scholar 

  8. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Cancer. 1985;56(9):18–928.

    Google Scholar 

  9. American College of Radiology Liver Imaging Reporting and Data System version 2018 core. https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS.

  10. Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150:835–53.

    Article  PubMed  Google Scholar 

  11. Kow AWC. Transplantation versus liver resection in patients with hepatocellular carcinoma. Transl Gastroenterol Hepatol. 2019;4:33. https://doi.org/10.21037/tgh.2019.05.06.

    Article  PubMed  Google Scholar 

  12. Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16:1344–54.

    Article  CAS  Google Scholar 

  13. Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology. 2016;278:563–77.

    Article  PubMed  Google Scholar 

  14. Segal E, Sirlin CB, Ooi C, Adler AS, Gollub J, Chen X, et al. Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat Biotechnol. 2007;25:675–80.

    Article  CAS  PubMed  Google Scholar 

  15. Zhou W, Zhang L, Wang K, Chen S, Wang G, Liu Z, et al. Malignancy characterization of hepatocellular carcinomas based on texture analysis of contrast-enhanced MR images. J Magn Reson Imaging. 2017;45:1476–84.

    Article  PubMed  Google Scholar 

  16. Zhang R, Xu L, Wen X, et al. A nomogram based on bi-regional radiomics features from multimodal magnetic resonance imaging for preoperative prediction of microvascular invasion in hepatocellular carcinoma. Quant Imaging Med Surg. 2019;9(9):1503–15.

    Article  PubMed  Google Scholar 

  17. Zhu W-S, Shi S-Y, Yang Z-H, Song C, Shen J. Radiomics model based on preoperative gadoxetic acid-enhanced MRI for predicting liver failure. World J Gastroenterol. 2020;26(11):1208–20.

    Article  CAS  PubMed  Google Scholar 

  18. Jiang H, Liu X, Chen J, Wei Y, Lee JM, Cao L, et al. Man or machine? Prospective comparison of the version 2018 EASL, LI-RADS criteria and a radiomics model to diagnose hepatocellular carcinoma. Cancer Imaging. 2019;19:84. https://doi.org/10.1186/s40644-019-0266-9.

    Article  PubMed  Google Scholar 

  19. Dong A, Yu H, Wang Y, Dong H, Zuo C. FDG PET/CT and enhanced CT imaging of tumor heterogeneity in hepatocellular carcinoma. Clin Nucl Med. 2014;39:808–10.

    Article  Google Scholar 

  20. Blanc-Durand P, Van Der Gucht A, Jreige M, Nicod-Lalonde M, Silva-Monteiro M, Prior JO, et al. Signature of survival: a 18 F-FDG PET based whole-liver Radiomic analysis predicts survival after 90 Y-TARE for hepatocellular carcinoma. Oncotarget. 2018;9:4549–58.

    Article  PubMed  Google Scholar 

  21. Wolfort RM, Papillion PW, Turnage RH, Lillien DL, Ramaswamy MR, Zibari GB. Role of FDG-PET in the evaluation and staging of hepatocellular carcinoma with comparison of tumor size, AFP level, and histologic grade. Int Surg. 2010;95:67–75.

    CAS  PubMed  Google Scholar 

  22. Lambin P, Leijenaar RTH, Deist TM, Peerlings J, de Jong EEC, van Timmeren J, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14:749–62.

    Article  PubMed  Google Scholar 

  23. Wakabayashi T, Ouhmich F, Gonzalez-Cabrera C, Felli E, Saviano A, Agnus V, et al. Radiomics in hepatocellular carcinoma: a quantitative review. Hepatol Int. 2019;13(5):546–59.

    Article  PubMed  Google Scholar 

  24. Raman SP, Schroeder JL, Huang P, et al. Preliminary data using computed tomography texture analysis for the classification of hypervascular liver lesions: generation of a predictive model on the basis of quantitative spatial frequency measurements–a work in progress. J Comput Assist Tomogr. 2015;39:383–95.

    PubMed  Google Scholar 

  25. Li M, Fu S, Zhu Y, et al. Computed tomography texture analysis to facilitate therapeutic decision making in hepatocellular carcinoma. Oncotarget. 2016;7:13248–59.

    Article  PubMed  Google Scholar 

  26. Chartrand G, Cheng PM, Vorontsov E, Drozdzal M, Turcotte S, Pal CJ, et al. Deep learning: a primer for radiologists. Radiographics. 2017;37:2113–31.

    Article  PubMed  Google Scholar 

  27. Litjens G, Kooi T, Bejnordi BE, Setio AAA, Ciompi F, Ghafoo-rian M, et al. A survey on deep learning in medical image analysis. Med Image Anal. 2017;42:60–88.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiology, Turgut Ozal Medical Center, Inonu University School of Medicine, 244280, Malatya, Turkey

    Aysegul Sagir Kahraman

  2. Liver Transplantation Institute, Inonu University, 244280, Malatya, Turkey

    Aysegul Sagir Kahraman

Authors
  1. Aysegul Sagir Kahraman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aysegul Sagir Kahraman.

Ethics declarations

Conflict of Interest

The author declares that she has no conflict of interest.

Code Availability

Not applicable.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sagir Kahraman, A. Radiomics in Hepatocellular Carcinoma. J Gastrointest Canc 51, 1165–1168 (2020). https://doi.org/10.1007/s12029-020-00493-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-020-00493-x

Keywords

Search

Navigation